The field of Pharmacovigilance is growing rapidly and its development is making tremendous impacts in medical sciences and pharmaceuticals. 7th International Conference and Exhibition on Pharmacovigilance emphasizes on how the importance and significance can be gauged by the fact that it has made huge advancements over the course of time and is continuing to influence various sectors. Main theme of 7th International Conference and Exhibition on Pharmacovigilance is “Ensuring Safer Therapeutics in Healthcare System”.

Preclinic​al trials involves the assessment of of potential therapeutic interventions in cells and animals. Clinical trials is the research conducted on patients using of patient data, disease mechanisms, therapeutic interventions and epidemiology. Clinical data is a key feature transforming basic research into medical care. Pre-Clinical and Clinical Trials involve human subjects to intervention to study the cause-and-effect relationship between a medical intervention and a health outcome. The perfect outcome of clinical trials is minimize risks, enhance benefits, and optimal use of an intervention of therapeutic drugs.

Adverse Drug Reaction (ADR) is the contrary reactions caused by taking a medication. Many Adverse Drug Reactions represent an overwhelming side effects of the drug's therapeutic effects. Adverse Drug Reactions of Drugs can be studied by reporting the mechanism of adverse drug reactions and maintaining the drug safety systems. This track is about expected and un-expected drug reactions and its reporting. Manufacturers, Professionals, and Consumers can report Post marketing reports on adverse effects.

Pharmacovigilance and Risk Management ia set of pharmacovigilance activities and interventions designed to identify, characterise, prevent or minimise risks relating to medicinal and therapeutic products including the assessment of the effectiveness of their clinical interventions.and combination therapies. Drug industry need to promote companies in pharmacovigilance practice to use information technology and to Review softwares used in pharmacovigilance and clinical trials. Monitoring unlicensed, off labels and orphan drugs is major task in risk management. Many experts from different pharmacovigilance CRO's , pharmacovigilance service providers and industrial delegates are participating in this conference to share their knowledge and discuss about the new updates.

Drug Safety is the pharmacological science ensuring safety and related to the collection, detection, assessment, monitoring, and prevention of adverse side effects with pharmaceutical products. In this track,we discuss Drug safety and its applications in various fields such as Softwares, Training etc.

The role of Good Pharmacovigilance Practice and Pharmacoepidemiology in Risk Management is mainly to increase the probability of beneficial effects of a drug in a population than the probability of adverse effects and to maintain the Good Reporting Practices by avoiding the major problems in risk management. Also it is important to concentrate on Signal investigation by gathering the information on new or unknown drug effects that is potentially caused by a medicine and that finally should lead to ensuring safety. The pharmacovigilance and clinical trials services providing companies should have thePharmacovigilance certification .

Good data quality management in pharmacovigilance can be relied only on information gathered from the collection of individual case safety reports and other pharmacoepidemiological data. Quality management consists of quality planning, quality control, quality assurance and quality improvements. The pharmacovigilance data processing cycle starts with data collection and, in computerised systems, data entry; the next step is data storage and maintenance; followed by data selection, retrieval and manipulation. The resulting data output is analysed and assessed. Finally, conclusions are drawn and decisions made. The quality of a pharmacovigilance data system can be defined as a measure of excellence or a state of being free from defects, deficiencies and significant variations and the data quality management includes all the activities that organizations use to direct, control and coordinate the quality of data.

Concept of Pharmacovigilance and its Significance enhances the impact of pharmacovigilance on patient welfare and public health and to know what is pharmacovigilance. This track gives a brief discussion on Pharmacovigilance role in healthcare system. Pharmacovigilance legislation gives an outlook on the rules and laws to follow in Pharmacovigilance practice. The Role of pharma industries in the improvement of pharmacovigilance system is very crucial to maintain the safety data, Detection and Evaluation of drug safety signals through manual and medical devices reporting. Pharmacovigilance scope also deals as Ecopharmacovigilance (EPV), pharmacoenvironmentology and pharmacovigilance in herbal medicines.

The clinical trial industry is constantly evolving with diversified clinical research technologies and new clinical studies are being launched at an ever-growing pace. Clinical trials have always been a vital part of the medicine development process, as they provide clinical data on the best ways for treating pathological disorders and diseases. The importance of diversity in industrial clinical trials and clinical research is to ensure that industrial clinical trials are doing due diligence and being as strategic as possible in their results.This diversity makes us to better understand the unmet medical needs of patients.

In Clinical Research, Statistics plays a prominent role in regulatory submissions. Statistical analysis of Pharmacovigilance can be achieved by several guidelines mainly ICH guidelines. Adverse Drug Reactions reports can also be considered for the regulatory submission.

Case Report in Clinical Trials plays a key role in Clinical Research. Case reports may be on unexpected association between diseases, disorders or symptoms. An unexpected event in the course of observing, treating a patient,possibilities of pathogenesis of a disease or an adverse effect.Unique or rare salient features of a disease or therapeutic approaches or a notable variation of the anatomical structures.

Due to the changing resources necessary to fulfil the regulatory requirements, some companies also choose to outsource or out task regulatory affairs to external service providers. Regulatory Affairs department is constantly evolving and growing and is the one which is least impacted during the Acquisition and Merger, and also during recession..The global pharmacovigilance market and Business opportunity bwas valued at USD 2,408.0 million in 2013 and is expected to grow at a CAGR of 12.6% during the forecast period. Phase III clinical trials market was the second largest and was valued at over USD 750.0 million in 2013.

Regulatory Affairs for clinical trials is the major part in the clinical trials approaches. Every clinical trial must be analysed according to the Regulatory Affairs Guidelines. There are several Regulatory Affairs departments depending upon the countries within evergrowing pace of companies. Global Harmonization in standards has led to consistent approach in regulatory submissions and hence its review.

Strategies for Growth in Pharma Environment track mainly focused in Strategic development towards FDA approval and Post market product Surveillances. The updates and advances in Pharmacovigilance Regulation system are discussed under Advances in Changing Pharmacovigilance Regulation System track.

Pharmacy practice is the field of pharmacy which involves developing the professional roles of pharmacists. It includes Disease-state management, Clinical drug interventions, Pharmacy professional development and pharmaceutical care, pharmaceutical compounding and health psychology, patient care, drug abuse prevention, prevention of drug interactions or minimisation of adverse events and drug incompatibility and community pharmacy.

ConferenceSeries is organizing splendorous Pharmaceutical conferences welcomes you to attend the 7th International Conference and Exhibition on Pharmacovigilance to be held during August 22-24, 2016 in Vienna, Austria. It focuses on the advancements in Pharmacovigilance and Risk Management.

The field of Pharmacovigilance is growing rapidly and its development is making tremendous impacts in medical sciences and pharmaceuticals. 7th International Conference and Exhibition on Pharmacovigilance emphasizes on how the importance and significance can be gauged by the fact that it has made huge advancements over the course of time and is continuing to influence various sectors. Main theme of 7th International Conference and Exhibition on Pharmacovigilance is “Ensuring Safer Therapeutics in Healthcare System”

Why to attend???

With members from around the world focused on learning about Pharmacovigilance and its advances; this is your best opportunity to reach the largest assemblage of participants from the Pharmacovigilance community. Conduct presentations, distribute information, meet with current and potential scientists, make a splash with new drug developments, and receive named recognition at this 3-days event. World-Renowned Speakers, the most recent techniques, developments, and the newest updates in Pharmacovigilance are Hallmarks of this Conference.

Target Audience:

Pharmacovigilance Students, Scientists

Pharmacovigilance Researchers

Pharmacovigilance Faculty

Medical Colleges

Pharmacovigilance Associations and Societies

Business Entrepreneurs

Training Institutes

Software Developing Companies

Manufacturing Medical Devices Companies

Data Management Companies

Summary:Pharmacovigilance 2016 welcomes Attendees, Presenters, and Exhibitors from all over the world to Vienna, Austria. We are delighted to invite you all to attend and register for the “7th International Conference and Exhibition on Pharmacovigilance” which is going to be held during August 22-24, 2016 at Vienna, Austria. The Organizing Committee is gearing up for an exciting and informative conference program including plenary lectures, symposia, workshops on a variety of topics, poster presentations and various programs for participants from all over the world. We invite you to join us at the Pharmacovigilance 2016, where you will be sure to have a meaningful experience with scholars from around the world. All the members of Pharmacovigilance 2016 Organizing Committee will look forward to meet you at Vienna, Austria.

Importance and Scope: Pharmacovigilance is the science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other medicine-related problem. The main purpose of pharmacovigilance is to improve the patient's safety and enhance his care in terms of the use of medicines, including paramedical interventions. Pharmacovigilance also supports public health programs by providing reliable information for the efficient assessment of the risk-benefit profile of medicines, contribute to the assessment of benefits, uses, side effects, harm, effectiveness and risk of medicines, encouraging the safe, rational and more effective (including cost-effective) use of various medicines. Promote education, understanding and clinical training in Pharmacovigilance and its effective availability to the public.

Why Vienna, Austria?

The global market for anti-counterfeiting packaging technologies is expected to increase from nearly $74.2 billion in 2015 to $135.6 billion in 2020, with a compound annual growth rate (CAGR) of 12.8% from 2015 to 2020.

According to the main association of social insurance carriers, the Austrian healthcare and social services sector employed a total of 229,092 people in 2010. Currently there are 266 public and private hospitals incl. specific hospitals, sanatoriums, rehab centers, and care facilities in Austria. The country counts 21.752 physicians, 53.970 nurses, 1.883 medical engineers, and 18.000 established physicians. More than 70 percent of the Austrian popularity have made use of at least one medical service in the recent four weeks. Among these are 81.4 percent of the Austrians who received outpatient care by the OPD “more than 12 months ago or never at all “The million euro expansions and new constructions of hospitals enhance Austria´s hospital quality to a considerable extent. The public expenditure in the healthcare sector amount to more than EUR 150 million per year.

The global pharmacovigilance market is segmented as follows:
Pharmacovigilance Market, by Phases of Drug Development:

Be a member and support us

Highlights from last year’s Convention!

Authorization Policy

By registering for the conference you grant permission to Conferenceseries to photograph, film or record and use your name, likeness, image, voice and comments and to publish, reproduce, exhibit, distribute, broadcast, edit and/or digitize the resulting images and materials in publications, advertising materials, or in any other form worldwide without compensation. Taking of photographs and/or videotaping during any session is prohibited. Contact us for any queries.